Metabolic Balance Study of FE203799 in Patients With SBS With Intestinal Insufficiency
Status:
Completed
Trial end date:
2019-10-28
Target enrollment:
Participant gender:
Summary
This is a repeated dose, open label trial investigating safety, efficacy, PD and PK of FE
203799 in 8 patients with SBS. The patients will receive a subcutaneous (SC) dose of 5 mg FE
203799 once weekly for 4 consecutive weeks, and efficacy parameters and PK will be assessed
after the fourth dose. Safety follow up assessments will be performed 4-6 weeks after the
last dose.